← Kura Oncology, Inc. (KURA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Kura Oncology, Inc. (KURA)
Pharmaceutical Preparations · market cap $978M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Kura Oncology (KURA) is a clinical-stage oncology company with 192 employees and a ~$964M market cap, built almost entirely around ziftomenib, a Phase 3 asset in acute myeloid leukemia (AML) with a PDUFA date of October 22, 2026. The company carries only ~$39M in cash against a reported runway of roughly 1.4 months, making near-term financing activity a near-certainty regardless of the regulatory outcome.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tipifarnib | Phase 2 | HNSCC |
| Ziftomenib | Phase 3 | Acute Myeloid Leukemia (AML) |
| Midazolam | Phase 2 | Advanced Malignant Neoplasm |
Price & technical context
3-month
-4.1%
6-month
+27.7%
12-month
+15.8%
52-wk range
$7.40–$13.59
vs 50-day MA
-4.6%
vs 200-day MA
+8.6%
Realized vol
64.5%
Max drawdown
-73.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KURA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.